A $511M impairment on its Canadian affiliate forces PMI to slash 2026 EPS guidance to $7.19–$7.34, even as Q2 revenue tops estimates at $11.2B

summarizeSummary

PMI reported Q2 revenue of $11.19B, beating estimates, but slashed full-year EPS guidance to $7.19–$7.34 from $8.31–$8.46 due to a $511M non-cash impairment on its Canadian affiliate RBH. The FDA authorized a modified risk claim for ZYN, and the company was acquitted in an Italian anti-corruption case.

check_boxKey Events · Earnings and Guidance · PM

• Full-Year EPS Guidance Slashed

  Full-year 2026 adjusted EPS guidance was cut to $7.19–$7.34, down from the $8.31–$8.46 range provided on June 2, 2026. The reduction stems primarily from a $511 million non-cash impairment on the RBH equity investment and unfavorable fair-value adjustments on equity securities.

• $511M RBH Impairment Charge

  A non-cash impairment of $511 million was recorded on the investment in Rothmans, Benson & Hedges (RBH), the deconsolidated Canadian subsidiary. The charge reflects updated five-year financial projections under RBH's court-approved restructuring plan, indicating a lower estimated fair value.

• Q2 Revenue Beats, Earnings Miss

  Net revenues rose 10.4% year over year to $11.19 billion, driven by smoke-free product growth. However, reported diluted EPS of $1.80 missed the $2.03 consensus, weighed down by the RBH impairment and a higher tax rate.

• FDA Authorizes ZYN Modified Risk Claim

  In June 2026, the FDA authorized a modified risk claim for 20 ZYN nicotine pouch varieties, allowing marketing with the claim: 'Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.'

auto_awesomeAnalysis · PM · Manufacturing

Philip Morris International posted a strong second-quarter revenue beat of $11.19 billion and adjusted EPS of $2.20, but the real story is the steep cut to full-year guidance. Management now projects adjusted EPS of $7.19–$7.34, a sharp drop from the $8.31–$8.46 range issued just two months ago. The main culprit is a $511 million non-cash impairment on its Canadian affiliate RBH, reflecting updated five-year projections under the court-approved restructuring plan. That charge, together with unfavorable fair-value adjustments on equity securities and a higher tax rate, pushed reported net earnings down 7.3% year over year. The guidance revision signals that the RBH situation is deteriorating faster than anticipated, and while the impairment is non-cash, it directly erodes book value. With the stock trading near its 52-week high, this negative update could prompt a reassessment of the premium multiple. On the brighter side, the FDA authorized a modified risk claim for ZYN in June, and the company was fully acquitted in the Italian anti-corruption case, removing a legal overhang. The 10-Q also introduces a segment realignment that separates International Smoke-Free, International Combustibles, and U.S. operations, offering better visibility into the smoke-free transformation. Investors will now focus on whether the RBH impairment is a one-time reset or signals deeper problems in the Canadian market, and whether the smoke-free business can sustain its growth trajectory to offset combustible declines.